July 16, 2019 — Uro Today
Trans-rectal ultrasound-guided 12-core systematic biopsy (SBx) is the standard diagnostic pathway for prostate cancer (PCa) because of a lack of sufficiently accurate imaging. Quantification of 3-D dynamic contrast-enhanced ultrasound (US) might open the way for a targeted procedure in which biopsies are directed at lesions suspicious on imaging. This work describes the expansion of contrast US dispersion imaging algorithms to 3-D and compares its performance against malignant and benign disease. Furthermore, we examined the feasibility of a multi-parametric approach to predict SBx-core outcomes using machine learning. An area under the receiver operating characteristic (ROC) curve of 0.76 and 0.81 was obtained for all PCa and significant PCa, respectively, an improvement over previous US methods. We found that prostatitis, in particular, was a source of false-positive readings.
Authors: Rogier R.Wildeboer*Ruud J.G.van Sloun*PintongHuang†HesselWijkstra*‡MassimoMischi*
⁎Lab of Biomedical Diagnostics, Department of Electrical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
†Department of Ultrasonography, Second Affiliated Hospital of Zhejiang University, Hangzhou, China
‡Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlandshttps://doi.org/10.1016/j.ultrasmedbio.2019.05.017Get rights and content